7%. The number of anastomoses and extent of cytoreduction were independent prognostic variables for major morbidity. In-hospital and 30-day mortality rates were 0% and 1.6%, respectively. Survival following CRS and HIPEC In 2003, Verwaal et al. reported results of a small prospective randomized controlled trial from the Netherlands Cancer Institute including 105 colorectal cancer patients who had

peritoneal metastases or positive cytology from ascites who were treated with CRS and HIPEC versus intravenous 5-fluorouracil (Table 4). This trial was updated with a minimal follow-up of 6 years in 2008 (25,26). The study showed a disease-specific survival of 22.2 selleck chem 17-DMAG months Inhibitors,research,lifescience,medical after CRS and HIPEC that was significantly better than the survival of 12.6 months after standard systemic chemotherapy. Elias et al. reported a cohort controlled study that compared outcomes of 48 patients treated with systemic chemotherapy to 48 who underwent CRS and HIPEC Inhibitors,research,lifescience,medical for peritoneal metastases for colorectal cancer (27). Most clinical and pathological variables were well matched; the median actuarial overall survivals were 23.9 months in the chemotherapy treated group and 62.7 months in the CRS and HIPEC group. The differences were statistically significant; the outcome of the CRS and HIPEC

treated group was better than most other reports of Inhibitors,research,lifescience,medical this treatment

approach in this patient population. The largest Inhibitors,research,lifescience,medical single study providing outcomes in patients following CRS and HIPEC in patients with colorectal cancer was reported by selleck chemicals llc Glehen and et al. That study included 506 patients treated at 28 institutions operated between 1987 and 2002 (18). The morbidity and mortality rates were 22.9% and 4%, respectively. The overall median survival was 19.2 months compared to the 62.7 months median survival reported by Elias et al. Patients in whom CRS was complete Inhibitors,research,lifescience,medical had a median survival of 32.4 months compared with 8.4 months for patients in whom complete CRS was not possible. Survival is only marginally improved by CRS and HIPEC in GSK-3 selected patients with peritoneal metastases from gastric cancer and is approximately 9 months (18,20). Patients with ovarian cancer who have undergone CRS and HIPEC had median survival rates ranging from 28 to 46 months and 5-year survival rates from 15% to 50% (21,24). For patients with diffuse malignant peritoneal mesothelioma (DMPM), a rare disease with relatively low incidence, median overall survivals between 34 and 92 months and 5-year survival rates from 33% to 59%, respectively, have been reported (17,23). Since patients with peritoneal metastases have a poor prognosis and limited longevity, measuring quality of life (QoL) endpoints for patients after CRS and HIPEC is very important.